10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited. Methods: From 2000 to 2010, 166 pts with a confirmed diagnosis of WDLPS/DDLPS were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 63 years (range 34-84). Thirty pts had WDLPS and 136 pts had DDLPS. Primary tumor sites were: retroperitoneum n=120 (73%), limb n=19 (11%), other n=27 (16%). 111 pts (67%) had metastatic disease (peritoneal sarcomatosis n=75; lung n=30, liver n=19, bone n=5) and 55 pts (33%) had locoregional unresectable disease. 27 pts (16%) had ≥ 2 metastatic sites. 103 pts (62%) received 1st line single agent chemotherapy. 131 pts (79%) received a 1st line anthracycline-containing regimen (doxorubicin n=64, doxorubicin + ifosfamide and/or dacarbazine: n=45, other: n=22). Non-anthracycline regimens were: metronomic cyclophosphamide or etoposide: n=17; trabectedin: n=4, others: n=14. RECIST objective response was observed in 18 pts (11%), all treated with anthracyclines. Response rate was higher in pts receiving combination chemotherapy: 17% vs 7%, p=0.03. 62 pts (37%) had stable disease > 6 months. Median progression-free survival (PFS) was 5.2 months (95% CI: 3.4-7.0). On multivariate analysis, performance status (PS) ≥ 2 was the sole factor significantly associated with poor PFS (Hazard ratio [HR]= 2.2; 95% CI 1.4–3.5; p3 (HR= 2.2; 95% CI 1.2–3.9; p = 0.01) were the sole factors significantly associated with poor OS. Conclusions: Chemotherapy is associated with a non-progression rate of about 50% in pts with advanced WDLPS/DDLPS. Combination chemotherapy gives higher response rate than single agent but appears to have no impact on PFS or OS. OS of pts with advanced WDLPS/DDLPS is poor, even if visceral metastatic disease is less frequent than in other sarcomas. Best supportive care should be considered in pts with poor PS.